Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 7/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10161329 | 0.83 | CHRNA7 (0.60) | SIGMAR1CHRNA7DRD2SLC18A3 | |
| SCHEMBL10162753 | 0.83 | OPRM1 (0.46) | OPRL1OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL10163591 | 0.80 | KMT2A (0.41) | CHRNA7DRD2SLC18A3 | |
| SCHEMBL10162738 | 0.78 | KMT2A (0.46) | CHRNA7DRD2 | |
| SCHEMBL10162628 | 0.78 | KMT2A (0.46) | CHRNA7DRD2 | |
| SCHEMBL10162449 | 0.78 | GAA (0.56) | SIGMAR1CHRNA7DRD2 | |
| SCHEMBL10163589 | 0.77 | KMT2A (0.43) | CHRNA7DRD2SLC18A3 | |
| SCHEMBL10162843 | 0.76 | KMT2A (0.44) | CHRNA7DRD2 | |
| SCHEMBL10130922 | 0.76 | DRD2 (0.41) | OPRL1OPRM1OPRD1OPRK1POLB | |
| SCHEMBL23374660 | 0.76 | DRD2 (0.66) | SIGMAR1DRD2ALDH1A1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | OPRL1 1784/4885OPRM1 203/4885OPRD1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.